sim™ - worlds first instrumented incontinence assessment ......•revenue usd 7b+ 2012, #79...

| © Simavita Limited | Commercial in Confidence

SIM™ - Worlds First Instrumented Incontinence Assessment Device

“An Investment in the Care of Ageing People” Presented by: Philippa Lewis – CEO

March 2014


Disclaimer

This document has been prepared by Simavita Limited (Simavita) and comprises written materials/slides for a presentation concerning Simavita.

This presentation has been prepared by Simavita for professional investors. The information contained in this presentation is for information purposes only and does not constitute an offer or solicitation to sell or to issue, or arrange to sell or issue, securities or other financial products. Any such offer or solicitation will be made only by means of a confidential information memorandum and in accordance with applicable securities and other laws. The information contained in this presentation is not investment or financial product advice, is not intended to be used as the basis for making an investment decision, and no specific recommendations are intended. The presentation has been prepared without taking into account the investment objectives, financial situation or particular need of any particular person.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in the presentation. To the maximum extent permitted by law, none of Simavita, its related companies and their respective directors, employees or advisers, nor any other person accepts any liability, including, without limitation, any liability arising out of fault .

Certain statements in this presentation are forward looking statements. These forward looking statements speak only as at the date of this presentation. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Simavita that the forward looking statements contained in this presentation are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct . Except for any statutory liability which cannot be excluded, each of Simavita, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.


Simavita Investment Case

• Aging global population – an investment “mega trend”

• Commercialized product – FDA clearance in place

• Digitized healthcare – reduced costs and superior accuracy

• Innovative, disruptive technology – smarter, better, cheaper

• Consumer choice – improved quality of care

• US Distribution Agreement in place for SIM™

• Other global distribution discussions advancing

• Global first mover advantage – strong patent protection

“An Investment in the Care of Ageing People”


Incontinence by Numbers

• 240 Million People in the western world are incontinent

• 15+ Million Incontinence assessments /year

• $6 Billion Assessment labor costs /year (nursing homes only)

• $9 Billion Continence products sold /year

• #2 Nursing home cost (after labor)

• 25%+ Total % of labor attributed to incontinence management in aged care facilities

• 70%+ Over 70% of residents in aged care are incontinent

Simavita’s Global Market

| © Simavita Limited | Commercial in Confidence PAGE 5 | © Simavita Limited | Commercial in Confidence

What is SIM™ SIM™ replaces inaccurate & labor intensive manual methods


Over USD 31m Spent on Research, Development and Commercialisation

• Incubator project from 1996

• First clinical trial 2004

• Philippa Lewis joins Simavita in 2007

• 40 sites in Australia used for “in market” product development, commercialisation and early sales

• US Distribution commencing by Medline in Q1 2014

• Global distribution discussions advancing in Canada and the EU


SIM™ World’s first Integrated and Instrumented Incontinence Assessment


SIM™ 72 Hour Bladder Chart SIMTM provides “Big Data”


SIM™ Summary observations Clinical guidelines


Published Peer Reviewed Research

Effective continence management can significantly improve the patients’ health outcome through early detection and management of urinary incontinence reducing a range of associated problems including:

• Reduce risk of urinary tract infections,

• Reduce risk of skin breakdown,

• Reduce risk of falls and adverse or aggressive behaviours.

Positive continence management leads to patient’s regaining independence, improved socialisation and overcomes depression associated with incontinence. Study outcome; Using the SIM™ caregivers were able to greatly improve incontinence management in a short-time frame - within 2 weeks.

• Reduced volume of urine voided into continence aids

• Increased number of successful toileting events

• Increased adherence to urinary continence care plans by staff

Statistically Significant (Journal of Clinical Nursing)


21%

23%

25%

0% 20% 40% 60% 80% 100%

EFFECTIVE TOILETING IMPROVEMENT

WASTE COST & LANDFILL REDUCTION

INCONTINENCE PRODUCT COST REDUCTION

Facility Cost Reduction The Australian Experience

Facility statistics post SIM™ implementation. 44 sites total of 2,367 beds


Significant Financial Benefits

Supports the Key Revenue Drivers for Residential Aged Care Facilities

• Reputation/Occupancy

• Government Funding

Delivers proven Cost savings

• Labor

• Consumables

• Time management

• Waste

Generates Critical Information for;

• Care Plans, Toileting, Staff Rostering, Product Prescription, Undiagnosed Related Conditions

Significant Improvement in Quality of Care

And Improved Quality of Care


Patient Benefits

• Less distress and physical intervention during assessment

• Right product selection (pads)

• Increased socialisation

• Less challenging and aggressive behaviours

• Less toileting

• Improved skin integrity – less ulcers

• Less falls

• Co-related conditions are identified and treated more quickly

Person centered evidence based


Strong IP

Proprietary Technology:

• Sensors • Algorithms • Incontinence management software and methods • Proprietary incontinence patient databank • Easy-to-use interface to complex data

Broad and deep Patent Portfolio:

• 8 patent families; numerous independent claims • 3 granted patents; 2 Australia, 1 US and Japan

- global coverage pending • Global exclusive license to two CSIRO patent portfolios • High value patenting fields: Incontinence management methods; other

clinical applications; algorithms and software; manufacturing methods


US Market

• Long Term Care facilities total 2,700,000 beds

• Urinary Incontinence costs $7,300 per bed per annum in labour alone1

• Or $19.9 billion based on 2,700,000 institutional beds

• SIM™ reduces labour and other costs and improves occupancy

• SIM results in a net savings of around $1,580 per bed per annum

• Community Care is estimated to be 170% larger than institutional care2

• Medical Inflation has averaged 3.68% since 2003 against 2.38% for standard CPI3

The Costs of Continence Management

1. Labour Costs associated with Urinary Incontinence in long –term care facilities (Shih YC et all 2003) 2. Costs of Urinary Incontinence and overactive bladder in the United States: a comparative study (Hu TW et all 2004) 3. BSL Data Series - Consumer Price Index - Medical Care (2000-2013)


MEDLINE

• Medline Industries Inc., head office, Chicago, Illinois

• Revenue USD 7b+ 2012, #79 private company Forbes

• 1100 sales reps and 37 distribution centers

• Largest privately held manufacturer and distributor of healthcare products in the US

• Leading provider of adult incontinence products to the US healthcare market

• High quality training through “Medline University”

• Manufactures incontinence products in Atlanta, Georgia

US Distribution Partner


US Market Simavita Revenue Model Per Site

• One off Software Sale

• Annual Software Licence

• Sale of Hardware

• Recurring Annual Sensor Sales

• Estimated revenue per site $15k-$70k per site dependant upon size, occupancy, frequency of assessments and consumable used per assessment

Revenue model for SIM™ in US Long Term Care


Long Term Care Facilities Global Revue - Commencement of Assessments


SIM™ Licensing and Royalty Applications Product spin outs

Current

• LTC Assessments Each product is developed with partner and sold

through their distribution channels. Product development and license fee paid to Simavita.

Generates revenue through Royalty

2013-14

• Com Care Assessments

2014-15

• LTC Everyday Royalty

• Data Management

2015-16

• Application B Royalty

• Application A Royalty

• Retail Everyday Royalty

• Com Care Everyday Royalty

2016-17

• Application D Royalty

• Application C Royalty


Simavita Limited

Cash on hand $7m

Monthly burn $500K

Growing revenue Australia, US

Listed on TSXV, Canada 6th December 2013, Code SV

Dual Listed on ASX, Australia 20th February 2014, Code SVA

Number of Shares on Issue 58,766,653

Share Price AUD$0.41

Market Capitalisation AUD$24.1m

Options/Warrants on Issue 9,186,207 Strike price s AUD$0.41 – 0.82, Expiry 3-5 years

Corporate Snapshot


Contacts

Philippa Lewis CEO Simavita Limited

Mobile + 61 415 245 159 Email [email protected] Website www.simavita.com

Australia

Jane Lowe – Investor Relations Account Director Buchan's Consulting

Mobile +61 411 117 774 Email [email protected] Website www.buchanwe.com.au


Thank you

sim™ - worlds first instrumented incontinence assessment ......•revenue usd 7b+ 2012, #79...

Documents